A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Pain Attributed to Osteoarthritis of the Knee
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs LEVI 04 (Primary)
- Indications Musculoskeletal pain; Pain
- Focus Adverse reactions; First in man
- Sponsors Levicept
- 02 Oct 2017 Planned End Date changed from 1 Feb 2019 to 1 Apr 2019.
- 02 Oct 2017 Planned primary completion date changed from 1 Feb 2019 to 1 Apr 2019.
- 31 Jul 2017 Status changed from not yet recruiting to recruiting.